Point-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify Pre-Op TIMI 45 – a pilot study.

The authors performed a proof-of-principle pilot study indicating that point-of-care platelet function testing predicts relevant blood loss after CABG in clopidogrel-treated patients. ROC analyses identified a specific threshold P2Y12 inhibitor level.

This publication supports an individualised perioperative management strategy: instead of waiting a fixed number of days after clopidogrel withdrawal, a sensitive laboratory result may help determine the optimal timing of surgery.

– Sibylle Kozek-Langenecker

Discuss this article on the Nataonline forum